Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 6, Issue 10

Bloodstream infections in cancer patients in central India: pathogens and trends of antimicrobial resistance over a 5-year period Open Access

Abstract

Bloodstream infection (BSI) is a common complication with a high fatality rate in cancer patients. There are notable variations in the epidemiology of BSI over time and among different countries. Infections due to multidrug-resistant organisms (MDROs) such as extended-spectrum beta-lactamases (ESBLs) and carbapenem-resistant (CRE) are increasing. This may lead to inadequate empirical antibiotic therapy, increasing the antimicrobial resistance (AMR) problem and unfavourable outcomes in these immunocompromised patients. There is paucity of data pertaining to AMR in such vulnerable patients from developing countries such as India. The aim of this study was to investigate the distribution of the bacterial pathogens causing BSI and the AMR trend in cancer patients in central India.

This single-centre retrospective observational study was conducted in a tertiary care cancer hospital. Patients with solid organ and haematological malignancies, both adults and paediatric, who had blood cultures sent to the microbiology laboratory from January 2018 to December 2022 were included. Blood cultures were processed using the BacT/ALERT 3D system (bioMérieux, France), and the identification of the bacteria and their antimicrobial susceptibility (AST) was performed using the Vitek 2 compact system (bioMérieux, France). Electronic medical records and microbiology lab records were used to retrieve the demographic and microbiological data. Microsoft Excel (RRID:SCR_016137) was used to enter and tabulate the data. Statistical analysis was performed using SPSS version 29 (RRID:SCR_002865).

A total of 687 isolates from 524 patients were studied. Gram-negative bacteria (64%) were the commonest cause of BSI in the studied patients, followed by Gram-positive cocci (25%) and fungal isolates (9%). Ten cases were polymicrobial. (=140) was the most common among the isolated pathogens, followed by species (=103), species (=102), and coagulase-negative staphylococci (CONS) (=92). Among the 140 isolates of , 66% were extended-spectrum β-lactamase (ESBL) producers and 26% were resistant to carbapenem. Among the 103 isolated species, 50% were carbapenem resistant and 36% were ESBL producers. Among enterobacterales, the CRE rate was 34%. Carbapenem resistance was seen in 25% of species and 53% of species isolates. species were the most resistant pathogens isolated. CONS comprised 56% of all Gram-positive isolates, followed by (36%), enterococci species (11%), and streptococci species (3%). Methicillin resistance was 60% in CONS and 64% in . One vancomycin-resistant enterococcus was isolated. Non- was the most common fungal pathogen. The sensitivity to fluconazole was 84% in non- species, while only one isolate of was resistant to fluconazole. The trend of pathogens was insignificant over 5 years, with Gram-negative bacteria being the commonest. Further, there was no significant change in the trend of ESBL and CRE resistance pattern over 5 years.

Gram-negative bacteria were the most common isolated pathogens from BSI with a higher antimicrobial resistance rate in cancer patients. The CRE rate of 34% is alarming, limiting the choices for empirical antibiotic therapy.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): bloodstream infections , haematological malignancies and multidrug-resistant organisms
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000673.v5
2024-10-29
2026-04-11

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/6/10/acmi000673.v5.html?itemId=/content/journal/acmi/10.1099/acmi.0.000673.v5&mimeType=html&fmt=ahah

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 2018; 68:394–424 [View Article]
     [Google Scholar]
  2. Zembower TR. Epidemiology of infections in cancer patients. Infectious Complications in Cancer Patients 2014; 16143–89 [View Article] [PubMed]
     [Google Scholar]
  3. Homsi J, Walsh D, Panta R, Lagman R, Nelson KA et al. Infectious complications of advanced cancer. Support Care Cancer 2000; 8:487–492 [View Article] [PubMed]
     [Google Scholar]
  4. Royo-Cebrecos C, Gudiol C, Ardanuy C, Pomares H, Calvo M et al. A fresh look at polymicrobial bloodstream infection in cancer patients. PLoS One 2017; 12:e0185768 [View Article] [PubMed]
     [Google Scholar]
  5. Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S et al. Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 2010; 47:184–188 [View Article] [PubMed]
     [Google Scholar]
  6. Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res 2014; 14:1–7 [View Article] [PubMed]
     [Google Scholar]
  7. WHO WHO report on surveillance of antibiotic consumption: 2016–2018 early implementation; 2018 https://iris.who.int/handle/10665/277359
  8. Gudiol C, Albasanz-Puig A, Cuervo G, Carratalà J. Understanding and managing sepsis in patients with cancer in the era of antimicrobial resistance. Front Med 2021; 8:636547 [View Article] [PubMed]
     [Google Scholar]
  9. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014; 68:321–331 [View Article] [PubMed]
     [Google Scholar]
  10. Prakash KP, Arora V, Geethanjali PP. Bloodstream bacterial pathogens and their antibiotic resistance pattern in Dhahira Region, Oman. Oman Med J 2011; 26:240–279 [View Article]
     [Google Scholar]
  11. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66:657–663 [View Article] [PubMed]
     [Google Scholar]
  12. WHO WHO publishes list of bacteria for which new antibiotics are urgently needed; 2017Feb17 https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
  13. Biswas S, Bhat V, Kelkar R. Carbapenem-resistant Enterobacteriaceae: A serious concern in cancer patients. Access Microbiology 2020; 2: [View Article]
     [Google Scholar]
  14. Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50:282–288 [View Article] [PubMed]
     [Google Scholar]
  15. Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Walsh TJ et al. Prevalence, risk factors, and outcomes of bacteremia caused by carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. Open Forum Infect Dis 2014; 1:S165 [View Article]
     [Google Scholar]
  16. Mendelson M, Matsoso MP. The World Health Organization global action plan for antimicrobial resistance. S Afr Med J 2015; 105:325 [View Article] [PubMed]
     [Google Scholar]
  17. CLSI Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020
  18. Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH et al. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol 2014; 89:423–428 [View Article] [PubMed]
     [Google Scholar]
  19. Obeng-Nkrumah N, Labi AK, Acquah ME, Donkor ES. Bloodstream infections in patients with malignancies: implications for antibiotic treatment in a Ghanaian tertiary setting. BMC Res Notes 2015; 8:742 [View Article] [PubMed]
     [Google Scholar]
  20. Carena A, Laborde A, Rossi IR, Guerrini G, Valledor A et al. Bacteremia in cancer patients. Comparison between solid and hematological tumors and impact on 30-day mortality. Open Forum Infect Dis 2016; 3:2309 [View Article]
     [Google Scholar]
  21. Bhat S, Muthunatarajan S, Mulki SS, Archana Bhat K, Kotian KH. Bacterial infection among cancer patients: analysis of isolates and antibiotic sensitivity pattern. Int J Microbiol 2021; 2021:8883700 [View Article] [PubMed]
     [Google Scholar]
  22. Perdikouri EIA, Arvaniti K, Lathyris D, Apostolidou Kiouti F, Siskou E et al. Infections due to multidrug-resistant bacteria in oncological patients: insights from a five-year epidemiological and clinical analysis. Microorganisms 2019; 7:277 [View Article] [PubMed]
     [Google Scholar]
  23. Worku M, Belay G, Tigabu A. Bacterial profile and antimicrobial susceptibility patterns in cancer patients. PLoS One 2022; 17:e0266919 [View Article] [PubMed]
     [Google Scholar]
  24. Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis 2020; 70:1068–1074 [View Article] [PubMed]
     [Google Scholar]
  25. Zain OM, Elsayed MY, Abdelkhalig SM, Abdelaziz M, Ibrahim SY et al. Bloodstream infection in cancer patients; susceptibility profiles of the isolated pathogens, at Khartoum Oncology Hospital, Sudan. Afr Health Sci 2022; 22:70–76 [View Article] [PubMed]
     [Google Scholar]
  26. Amanati A, Sajedianfard S, Khajeh S, Ghasempour S, Mehrangiz S et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis 2021; 21:636 [View Article] [PubMed]
     [Google Scholar]
  27. Zimmer AJ, Stohs E, Meza J, Arnold C, Baddley JW et al. Bloodstream infections in hematologic malignancy patients with fever and neutropenia: are empirical antibiotic therapies in the United States still effective?. Open Forum Infect Dis 2022; 9:ofac240 [View Article] [PubMed]
     [Google Scholar]
  28. Becker K, Both A, Weißelberg S, Heilmann C, Rohde H. Emergence of coagulase-negative staphylococci. Expert Rev Anti Infect Ther 2020; 18:349–366 [View Article] [PubMed]
     [Google Scholar]
  29. Kara Ali R, Surme S, Balkan II, Salihoglu A, Sahin Ozdemir M et al. An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality. Ann Hematol 2020; 99:1925–1932 [View Article] [PubMed]
     [Google Scholar]
  30. Mihalcea AR, Garnier N, Faure-Conter C, Rama N, Renard C et al. Alarming upward trend in multidrug-resistant bacteria in a large cohort of immunocompromised children: a four-year comparative study. Cancers 2023; 15:938 [View Article] [PubMed]
     [Google Scholar]
  31. Bhattacharya S, Goel G, Mukherjee S, Bhaumik J, Chandy M. Epidemiology of antimicrobial resistance in an Oncology Center in Eastern India. Infect Control Hosp Epidemiol 2015; 36:864–866 [View Article]
     [Google Scholar]
  32. Kim SB, Min YH, Cheong JW, Kim JS, Kim SJ et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis 2014; 46:81–88 [View Article] [PubMed]
     [Google Scholar]
  33. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:427–431 [View Article] [PubMed]
     [Google Scholar]
  34. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98:1826–1835 [View Article] [PubMed]
     [Google Scholar]
  35. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14:882–913 [View Article] [PubMed]
     [Google Scholar]
  36. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33:947–953 [View Article]
     [Google Scholar]
  37. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009; 15:47–53 [View Article]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000673.v5
Loading
Bloodstream infections in cancer patients in central India: pathogens and trends of antimicrobial resistance over a 5-year period
Access Microbiology 6, 000673.v5 (2024); https://doi.org/10.1099/acmi.0.000673.v5
/content/journal/acmi/10.1099/acmi.0.000673.v5
/content/journal/acmi/10.1099/acmi.0.000673.v5
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error